Oxford BioMedica PLC has completed the acquisition of the remaining 10% stake in its US subsidiary from Massachusetts-based biotechnology firm Q32 Bio Inc., achieving full ownership of its Bedford facility and strengthening its position in the expanding viral vector manufacturing market.
The Oxford, England-based cell and gene therapy contract development and manufacturing organization (CDMO) exercised its call option through wholly-owned subsidiary OXB US Inc. to acquire the final 10% interest in OXB US LLC from Q32 on March 1, 2025. The stake was originally held by Homology Medicines Inc., which merged with Q32 in 2024.
Strategic Expansion in Key Market
"The progression to full ownership of our US business marks an important step for OXB. It strengthens our position in a key market and helps meet growing demand for high-quality vector manufacturing – a critical enabler of the expanding cell and gene therapy market," said Chief Executive Officer Frank Mathias.
The acquisition aligns with Oxford BioMedica's global strategy and supports long-term growth in the viral vector manufacturing sector. The company's presence in the US, alongside existing sites in the UK and France, provides clients with access to deep expertise across AAV and lentiviral-based therapies.
Facility Capabilities and Integration
OXB US LLC was originally established in Bedford, Massachusetts, in 2022 as an adeno-associated virus (AAV) manufacturing and innovation business. The facility spans 96,000 square feet and offers both lentiviral and AAV vector capabilities.
The site has been fully integrated into OXB's global network, successfully completing the tech transfer of its lentiviral platform to the facility in 2024. The Bedford location has supported the onboarding of multiple new programs in the US as part of OXB's global cell and gene therapy development and manufacturing network.
Global Manufacturing Network
Through OXB's expanded network, the company can support clients globally across all key vector types, from early-stage development through to commercialization. The company leverages 30 years of experience in viral vectors, which serve as the driving force behind the majority of cell and gene therapies.
Oxford BioMedica collaborates with pharmaceutical and biotechnology companies worldwide, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. The company's capabilities are supported by robust quality-assurance systems, analytical methods and regulatory expertise.
Following the announcement, shares in Oxford BioMedica were down 3.0% at 311.50 pence in London trading on Monday.
